A recent study proposed a role for elevated CDK6 expression in the intrinsic resistance of NSCLC and superficial spreading melanomas to CDK4i/6i, however, we find the opposite in ALM models whereby CDK6 expression directly trends with CDK4i/6i efficacy. This evidence concerns the gene CDK6 and acral lentiginous melanoma.